Cerus
Open
$2.03
Prev. Close
$2.03
High
$2.03
Low
$2.02
Market Snapshot
$368.81M
-23.6
-0.11
$201.32M
275
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 275 full-time employees. The firm is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Cerus reported a 24% revenue increase to $53.7 million for Q1 2026, raising its full-year guidance to $227-$231 million, reflecting strong industry demand.
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 275 full-time employees. The firm is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Recently from Cashu
Cerus Corporation Strengthens Blood Safety Commitment Amid Economic Challenges and Market Volatility
Cerus Corporation Maintains Focus on Blood Safety Amid Economic Volatility In light of recent fluctuations in U.S. stock futures, Cerus Corporation remains steadfast in its commitment to enhancing blo…
Cerus Corporation Reports Strong Revenue Growth and Strategic Advances in Blood Safety Solutions
Cerus Corporation's Growth in Blood Safety Solutions Drives Future Potential Cerus Corporation (NASDAQ:CERS) reports a robust financial outcome for the fourth quarter of 2026, emphasizing its role in…
Cerus Corporation Reports Strong Q4 Growth, Optimistic Outlook for Blood Safety Solutions
## Cerus Corporation: Advancing Blood Safety Solutions Amid Strong Financial Performance Cerus Corporation continues to demonstrate its growth trajectory following the recent release of its Q4 earning…
Cerus Corporation Set for Key Earnings Report Amid Innovations in Blood Safety Technologies
### Cerus Corporation Prepares for Significant Earnings Report Amidst Innovations in Blood Safety Technologies Cerus Corporation stands on the brink of revealing its quarterly earnings report on March…